{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T22:37:17Z","timestamp":1788043037444,"version":"build-2784847793"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-68013-6","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T03:31:06Z","timestamp":1721791866000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical outcomes of immunomodulation therapy in immunocompromised patients with severe Covid-19 and high oxygen requirement"],"prefix":"10.1038","volume":"14","author":[{"given":"Avigayil","family":"Goldstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Neuberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazeed Qassem","family":"Darawsha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khetam","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tali","family":"Shafat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Grupel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"strahilevitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Israel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronen","family":"Ben-Ami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meital","family":"Elbaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronza","family":"Najjar-Debbiny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihad","family":"Bishara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Shlomai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Landes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"issue":"1","key":"68013_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ajpath.2020.08.009","volume":"191","author":"JN Gustine","year":"2021","unstructured":"Gustine, J. N. & Jones, D. Immunopathology of Hyperinflammation in COVID-19. Am. J. Pathol. 191(1), 4\u201317 (2021).","journal-title":"Am. J. Pathol."},{"issue":"6","key":"68013_CR2","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.chom.2020.04.009","volume":"27","author":"EJ Giamarellos-Bourboulis","year":"2020","unstructured":"Giamarellos-Bourboulis, E. J. et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe 27(6), 992-1000.e3 (2020).","journal-title":"Cell Host Microbe"},{"issue":"1","key":"68013_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41591-021-01643-9","volume":"28","author":"FL van de Veerdonk","year":"2022","unstructured":"van de Veerdonk, F. L. et al. A guide to immunotherapy for COVID-19. Nat. Med. 28(1), 39\u201350 (2022).","journal-title":"Nat. Med."},{"issue":"10349","key":"68013_CR4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0140-6736(22)01109-6","volume":"400","author":"O Abani","year":"2022","unstructured":"Abani, O. et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial and updated meta-analysis. The Lancet 400(10349), 359\u2013368 (2022).","journal-title":"The Lancet"},{"issue":"9","key":"68013_CR5","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"AC Kalil","year":"2021","unstructured":"Kalil, A. C. et al. Baricitinib plus Remdesivir for hospitalized adults with Covid-19. N. Engl. J. Med 384(9), 795\u2013807 (2021).","journal-title":"N. Engl. J. Med"},{"issue":"12","key":"68013_CR6","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","volume":"9","author":"VC Marconi","year":"2021","unstructured":"Marconi, V. C. et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir. Med. 9(12), 1407\u20131418 (2021).","journal-title":"Lancet Respir. Med."},{"issue":"6","key":"68013_CR7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jama.2021.11330","volume":"326","author":"M Shankar-Hari","year":"2021","unstructured":"Shankar-Hari, M. et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A Meta-analysis. Jama 326(6), 499\u2013518 (2021).","journal-title":"Jama"},{"issue":"3","key":"68013_CR8","doi-asserted-by":"publisher","first-page":"100628","DOI":"10.1016\/j.trre.2021.100628","volume":"35","author":"G Ao","year":"2021","unstructured":"Ao, G. et al. The association between severe or death COVID-19 and solid organ transplantation: A systematic review and meta-analysis. Transpl. Rev. (Orlando) 35(3), 100628 (2021).","journal-title":"Transpl. Rev. (Orlando)"},{"issue":"25","key":"68013_CR9","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1182\/blood.2020008824","volume":"136","author":"A Vijenthira","year":"2020","unstructured":"Vijenthira, A. et al. Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients. Blood 136(25), 2881\u20132892 (2020).","journal-title":"Blood"},{"issue":"11","key":"68013_CR10","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1097\/QAD.0000000000002968","volume":"35","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. An updated meta-analysis on the association between HIV infection and COVID-19 mortality. Aids 35(11), 1875\u20131878 (2021).","journal-title":"Aids"},{"key":"68013_CR11","unstructured":"Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Bethesda (MD): National Institutes of Health (US), 2021."},{"key":"68013_CR12","doi-asserted-by":"crossref","unstructured":"Cesaro S, et al. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). Leukemia 2022; 36(6): 1467\u201380.","DOI":"10.1038\/s41375-022-01578-1"},{"issue":"7","key":"68013_CR13","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/blood.2022016089","volume":"140","author":"F El Chaer","year":"2022","unstructured":"El Chaer, F., Auletta, J. J. & Chemaly, R. F. How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies. Blood 140(7), 673\u2013684 (2022).","journal-title":"Blood"},{"key":"68013_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac724","author":"A Bhimraj","year":"2022","unstructured":"Bhimraj, A. et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciac724 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"68013_CR15","unstructured":"Centers for Disease Control and Prevention. Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare professionals.\u200f (2022)."},{"key":"68013_CR16","unstructured":"National Institutes of Health. COVID-19 treatment guidelines. Available at: https:\/\/www.covid19treatmentguidelines.nih.gov\/."},{"issue":"9","key":"68013_CR17","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.cmi.2022.05.005","volume":"28","author":"M Tr\u00f8seid","year":"2022","unstructured":"Tr\u00f8seid, M. et al. Immunocompromised patients have been neglected in Covid- 19 trials: A call for action. Clin. Microbiol. Infect. 28(9), 1182\u20131183 (2022).","journal-title":"Clin. Microbiol. Infect."},{"issue":"8","key":"68013_CR18","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1097\/TP.0000000000004200","volume":"106","author":"RK Avery","year":"2022","unstructured":"Avery, R. K. Update on COVID-19 therapeutics for Solid organ transplant recipients Including Omicron Surge. Transplantation 106(8), 1528\u20131537 (2022).","journal-title":"Transplantation"},{"key":"68013_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/jcm10081551","volume":"10","author":"M Bodro","year":"2021","unstructured":"Bodro, M. et al. Use of anti-cytokine therapy in kidney transplant recipients with COVID-19. J. Clin. Med. 10, 8 (2021).","journal-title":"J. Clin. Med."},{"issue":"11","key":"68013_CR20","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1111\/ajt.16314","volume":"20","author":"MR Pereira","year":"2020","unstructured":"Pereira, M. R. et al. Tocilizumab for severe COVID-19 in solid organ transplant recipients: A matched cohort study. Am. J. Transpl. 20(11), 3198\u20133205 (2020).","journal-title":"Am. J. Transpl."},{"issue":"3","key":"68013_CR21","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3390\/idr14030052","volume":"14","author":"A Corriero","year":"2022","unstructured":"Corriero, A. et al. COVID-19 variants in critically ill patients: A comparison of the Delta and Omicron variant profiles. Infect. Dis. Rep. 14(3), 492\u2013500 (2022).","journal-title":"Infect. Dis. Rep."},{"issue":"3","key":"68013_CR22","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4266\/acc.2022.00675","volume":"37","author":"P Tandon","year":"2022","unstructured":"Tandon, P. et al. The fourth wave: Vaccination status and intensive care unit mortality at a large hospital system in New York City. Acute Crit. Care 37(3), 339\u2013346 (2022).","journal-title":"Acute Crit. Care"},{"issue":"1","key":"68013_CR23","doi-asserted-by":"publisher","first-page":"6025","DOI":"10.1038\/s41467-022-33801-z","volume":"13","author":"N de Prost","year":"2022","unstructured":"de Prost, N. et al. Clinical phenotypes and outcomes associated with SARS-CoV-2 variant Omicron in critically ill French patients with COVID-19. Nat. Commun. 13(1), 6025 (2022).","journal-title":"Nat. Commun."},{"key":"68013_CR24","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1200\/GO.21.00072","volume":"7","author":"AR Nadkarni","year":"2021","unstructured":"Nadkarni, A. R., Vijayakumaran, S. C., Gupta, S. & Divatia, J. V. Mortality in cancer patients with COVID-19 who are admitted to an ICU or who have severe COVID-19: A systematic review and meta-analysis. JCO Glob. Oncol. 7, 1286\u20131305 (2021).","journal-title":"JCO Glob. Oncol."},{"issue":"42","key":"68013_CR25","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.15585\/mmwr.mm7142a4","volume":"71","author":"A Britton","year":"2022","unstructured":"Britton, A. et al. Effectiveness of COVID-19 mRNA vaccines against COVID-19-associated hospitalizations among immunocompromised adults during SARS-CoV-2 Omicron Predominance\u2014VISION network, 10 states, December 2021-August 2022. MMWR Morb. Mortal Wkly Rep. 71(42), 1335\u20131342 (2022).","journal-title":"MMWR Morb. Mortal Wkly Rep."},{"issue":"16","key":"68013_CR26","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","volume":"384","author":"AC Gordon","year":"2021","unstructured":"Gordon, A. C. et al. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. N. Engl. J. Med. 384(16), 1491\u20131502 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"10285","key":"68013_CR27","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"PW Horby","year":"2021","unstructured":"Horby, P. W. et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. The Lancet 397(10285), 1637\u20131645 (2021).","journal-title":"The Lancet"},{"issue":"12","key":"68013_CR28","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.4187\/respcare.08779","volume":"66","author":"AK Singh","year":"2021","unstructured":"Singh, A. K. et al. Impact of timing of Tocilizumab use in hospitalized patients with SARS-CoV-2 infection. Respir. Care 66(12), 1805\u20131814 (2021).","journal-title":"Respir. Care"},{"issue":"6","key":"68013_CR29","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1056\/NEJMsb2104756","volume":"385","author":"L Corey","year":"2021","unstructured":"Corey, L. et al. SARS-CoV-2 variants in patients with immunosuppression. N. Engl. J. Med. 385(6), 562\u2013566 (2021).","journal-title":"N. Engl. J. Med."},{"key":"68013_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1126\/sciimmunol.abc5367","volume":"5","author":"FR Spinelli","year":"2020","unstructured":"Spinelli, F. R., Conti, F. & Gadina, M. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19. Sci. Immunol. 5, 47 (2020).","journal-title":"Sci. Immunol."},{"issue":"1","key":"68013_CR31","doi-asserted-by":"publisher","first-page":"12703","DOI":"10.1038\/s41598-021-92220-0","volume":"11","author":"N Shafran","year":"2021","unstructured":"Shafran, N. et al. Secondary bacterial infection in COVID-19 patients is a stronger predictor for death compared to influenza patients. Sci. Rep. 11(1), 12703 (2021).","journal-title":"Sci. Rep."},{"issue":"13","key":"68013_CR32","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1056\/NEJMc2111462","volume":"385","author":"VG Hall","year":"2021","unstructured":"Hall, V. G. et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N. Engl. J. Med. 385(13), 1244\u20131246 (2021).","journal-title":"N. Engl. J. Med."},{"key":"68013_CR33","doi-asserted-by":"publisher","first-page":"e068632","DOI":"10.1136\/bmj-2021-068632","volume":"376","author":"ARYB Lee","year":"2022","unstructured":"Lee, A. R. Y. B. et al. Efficacy of covid-19 vaccines in immunocompromised patients: Systematic review and meta-analysis. BMJ 376, e068632 (2022).","journal-title":"BMJ"},{"issue":"6","key":"68013_CR34","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S2213-2600(21)00184-3","volume":"9","author":"Y Shostak","year":"2021","unstructured":"Shostak, Y. et al. Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine. Lancet Respir. Med. 9(6), e52\u2013e53 (2021).","journal-title":"Lancet Respir. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68013-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68013-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68013-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T03:35:12Z","timestamp":1721792112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68013-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["68013"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-68013-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"assertion":[{"value":"10 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16985"}}